Literature DB >> 1607250

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.

J M Cain1, P Y Liu, D E Alberts, H H Gallion, L Laufman, J O'Sullivan, G Weiss, J N Bickers.   

Abstract

A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1607250     DOI： 10.1007/bf01275473

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

Review 1.  New anticancer agents.

Authors:  G R Weiss; C L Arteaga; T D Brown; J B Craig; G S Harman; K A Havlin; J M Koeller; J G Kuhn; D D Von Hoff
Journal:  Cancer Chemother Biol Response Modif       Date:  1988

Review 2.  Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.

Authors:  H G Chun; B Davies; D Hoth; M Suffness; J Plowman; K Flora; C Grieshaber; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Antitumor activity of didemnin B in the human tumor stem cell assay.

Authors:  T L Jiang; R H Liu; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.

Authors:  K L Rinehart; J B Gloer; R G Hughes; H E Renis; J P McGovren; E B Swynenberg; D A Stringfellow; S L Kuentzel; L H Li
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728
  5 in total
  6 in total

1.  Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

Authors:  A Mittelman; H G Chun; C Puccio; N Coombe; T Lansen; T Ahmed
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Therapeutic potential of marine peptides in cervical and ovarian cancers.

Authors:  Salman Ahmed; Haroon Khan; Sajad Fakhri; Michael Aschner; Wai San Cheang
Journal:  Mol Cell Biochem       Date:  2021-12-02       Impact factor: 3.396

Review 3.  Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Authors:  D M Shin; P Y Holoye; A Forman; R Winn; R Perez-Soler; S Dakhil; J Rosenthal; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Isolation and characterization of marine Brevibacillus sp. S-1 collected from South China Sea and a novel antitumor peptide produced by the strain.

Authors:  Lanhong Zheng; Yao Yi; Jia Liu; Xiukun Lin; Kangli Yang; Mei Lv; Xinwen Zhou; Jianhua Hao; Junzhong Liu; Yuan Zheng; Mi Sun
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

Review 5.  Bioactive Peptide of Marine Origin for the Prevention and Treatment of Non-Communicable Diseases.

Authors:  Ratih Pangestuti; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2017-03-09       Impact factor: 5.118

6.  Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.

Authors:  Andrea Perne; Markus K Muellner; Magdalena Steinrueck; Nils Craig-Mueller; Julia Mayerhofer; Ilse Schwarzinger; Mathew Sloane; Iris Z Uras; Gregor Hoermann; Sebastian M B Nijman; Matthias Mayerhofer
Journal:  PLoS One       Date:  2009-12-16       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.